Trial · NCT00504660

6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients

NCT00504660, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2012-01-11

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients. Trials, record NCT00504660. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00504660

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
NCT number: NCT00504660
Status: Completed
Phases: Phase 2
Enrollment: 75 participants, actual
Lead sponsor: M.D. Anderson Cancer Center
Conditions: Anaplastic Glioma of Brain, Glioblastoma Multiforme, Brain Cancer
Interventions: Capecitabine, Celecoxib (Celebrex), Temozolomide, Lomustine, 6-Thioguanine
First posted: 2007-07-20
Last updated: 2012-01-11
Results first posted: 2012-01-11

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	12 Month-progression-free Survival for Participants With Anaplastic Tumors	12 months	Progression-free Survival (PFS) at 12 months measured as percentage of participants that are alive and progression-free at 12 months (anaplastic tumors). A combination of neurological examination and MRI brain scan used to define overall response or progression.
Primary	6 Month Progression-free Survival for Participants With Glioblastoma	6 months	Progression-free Survival (PFS) at 6 months measured as percentage of participants that are alive and progression-free at 6 months (glioblastoma multiforme). A combination of neurological examination and MRI brain scan used to define overall response or progression.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	12 Month-progression-free Survival for Participants With Anaplastic Tumors	12 months	Results from TMZ and CCNU treatment arms (Anaplastic Tumor-Glioma Arms 1 \& 2) were combined in the final analysis because there was no statistically significant difference between them.	percentage of participants	NUMBER
PRIMARY	6 Month Progression-free Survival for Participants With Glioblastoma	6 months		percentage of participants	NUMBER

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
12 Month-progression-free Survival for Participants With Anaplastic Tumors	Participants With Recurrent Anaplastic Glioma		44	5	percentage of participants
6 Month Progression-free Survival for Participants With Glioblastoma	Participants With Glioblastoma Multiforme		14		percentage of participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Anaplastic Tumors	31
Overall Study	STARTED	Glioblastoma Multiforme	43
Overall Study	COMPLETED	Anaplastic Tumors	31
Overall Study	COMPLETED	Glioblastoma Multiforme	43
Overall Study	NOT COMPLETED	Anaplastic Tumors	0
Overall Study	NOT COMPLETED	Glioblastoma Multiforme	0

Source ClinicalTrials.gov

Adverse events116

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	ALKALINE PHOSPHATASE	Metabolism and nutrition disorders	Anaplastic Tumors	5	31	6
other	ALKALINE PHOSPHATASE	Metabolism and nutrition disorders	Glioblastoma Multiforme	7	43	9
other	ALLERGIC RHINITIS	Immune system disorders	Anaplastic Tumors	4	31	4
other	ALLERGIC RHINITIS	Immune system disorders	Glioblastoma Multiforme	6	43	6
other	ALOPECIA	Skin and subcutaneous tissue disorders	Anaplastic Tumors	5	31	5
other	ALOPECIA	Skin and subcutaneous tissue disorders	Glioblastoma Multiforme	7	43	8
other	ALT SGPT	Metabolism and nutrition disorders	Anaplastic Tumors	10	31	13
other	ALT SGPT	Metabolism and nutrition disorders	Glioblastoma Multiforme	14	43	18
other	ANEMIA	Blood and lymphatic system disorders	Anaplastic Tumors	6	31	16
other	ANEMIA	Blood and lymphatic system disorders	Glioblastoma Multiforme	3	43	4

1 to 10 of 116Source ClinicalTrials.gov

See all 116 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Anaplastic Tumors
Total, all-cause mortality	Glioblastoma Multiforme
Total, other adverse events	Anaplastic Tumors	31	31
Total, other adverse events	Glioblastoma Multiforme	43	43
Total, serious adverse events	Anaplastic Tumors	8	31
Total, serious adverse events	Glioblastoma Multiforme	16	43

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Anaplastic Tumors vs Glioblastoma Multiforme: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00504660

GET https://conductscience.org/api/trials/v1/NCT00504660/events?page=2

API reference For AI assistants